JP2023541522A - 低分子量タンパク質分解物質及びその適用 - Google Patents

低分子量タンパク質分解物質及びその適用 Download PDF

Info

Publication number
JP2023541522A
JP2023541522A JP2023507550A JP2023507550A JP2023541522A JP 2023541522 A JP2023541522 A JP 2023541522A JP 2023507550 A JP2023507550 A JP 2023507550A JP 2023507550 A JP2023507550 A JP 2023507550A JP 2023541522 A JP2023541522 A JP 2023541522A
Authority
JP
Japan
Prior art keywords
alkyl
compound
pharmaceutical composition
unsubstituted
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541522A5 (https=
Inventor
シルバイン コッテンス
ニアル ディツキンソン
カタジナ カチャノフスカ
クシシュトファ オドジブウ
ロマン プルタ
ミハウ バルチャク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Captor Therapeutics SA
Original Assignee
Captor Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Captor Therapeutics SA filed Critical Captor Therapeutics SA
Publication of JP2023541522A publication Critical patent/JP2023541522A/ja
Publication of JP2023541522A5 publication Critical patent/JP2023541522A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023507550A 2020-08-03 2021-08-03 低分子量タンパク質分解物質及びその適用 Pending JP2023541522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL2020000066 2020-08-03
PLPCT/PL2020/000066 2020-08-03
PCT/EP2021/071694 WO2022029138A1 (en) 2020-08-03 2021-08-03 Low molecular weight protein degraders and their applications

Publications (2)

Publication Number Publication Date
JP2023541522A true JP2023541522A (ja) 2023-10-03
JP2023541522A5 JP2023541522A5 (https=) 2024-07-25

Family

ID=72193535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507550A Pending JP2023541522A (ja) 2020-08-03 2021-08-03 低分子量タンパク質分解物質及びその適用

Country Status (11)

Country Link
US (1) US20240294489A1 (https=)
EP (1) EP4188373A1 (https=)
JP (1) JP2023541522A (https=)
KR (1) KR20230048373A (https=)
CN (1) CN116457344A (https=)
AU (1) AU2021319847A1 (https=)
BR (1) BR112023001956A2 (https=)
CA (1) CA3186919A1 (https=)
IL (1) IL300308A (https=)
MX (1) MX2023001401A (https=)
WO (1) WO2022029138A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524765A (ja) * 2021-06-28 2024-07-05 成都分迪葯業有限公司 アミド化合物とその応用
JP2024544507A (ja) * 2021-11-09 2024-12-03 コリア リサーチ インスティテュート オブ ケミカル テクノロジー グルタルイミド母核を有するイソインドリノン誘導体及びその用途
JP2024546851A (ja) * 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
JP2025502928A (ja) * 2021-12-08 2025-01-30 グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド Ｅ３ユビキチンリガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082301A (zh) * 2021-11-05 2023-05-09 上海美志医药科技有限公司 具有降解gspt1活性的化合物及其应用
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2024096753A1 (en) 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522803A (ja) * 2008-05-30 2011-08-04 セルジーン コーポレイション ５−置換イソインドリン化合物
JP2017525757A (ja) * 2014-07-11 2017-09-07 セルジーン コーポレイション 抗増殖性化合物及びその使用方法
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019038717A1 (en) * 2017-08-23 2019-02-28 Novartis Ag 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
WO2019241274A1 (en) * 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
JP2020506922A (ja) * 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CL2007002513A1 (es) * 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP4467143B1 (en) 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
CA3075813A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
CN113347974A (zh) * 2018-12-31 2021-09-03 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的组合物和使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522803A (ja) * 2008-05-30 2011-08-04 セルジーン コーポレイション ５−置換イソインドリン化合物
JP2017525757A (ja) * 2014-07-11 2017-09-07 セルジーン コーポレイション 抗増殖性化合物及びその使用方法
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
JP2020506922A (ja) * 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019038717A1 (en) * 2017-08-23 2019-02-28 Novartis Ag 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
WO2019241274A1 (en) * 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Protein degradation via CRL4CRBN ubiquitin ligase: Discovery and structure-activity relationships of", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, JPN6025021476, 2018, pages 492 - 503, ISSN: 0005802161 *
"抗がん作用を持つ新たなセレブロンモジュレーターの開発", ファルマシア, vol. 53, no. 4, JPN6025021475, 2018, pages 328 - 332, ISSN: 0005802162 *
PIRALI, T. ET AL.: "Application of Deuterium in Medicinal Chemistry", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, JPN6026007005, 2019, pages 5276 - 5297, ISSN: 0005802159 *
日本学術振興会, フッ素化学入門−先端テクノロジーに果たすフッ素化学の役割, JPN6016027567, 2005, pages 398 - 403, ISSN: 0005802160 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524765A (ja) * 2021-06-28 2024-07-05 成都分迪葯業有限公司 アミド化合物とその応用
JP2024544507A (ja) * 2021-11-09 2024-12-03 コリア リサーチ インスティテュート オブ ケミカル テクノロジー グルタルイミド母核を有するイソインドリノン誘導体及びその用途
JP2025502928A (ja) * 2021-12-08 2025-01-30 グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド Ｅ３ユビキチンリガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
JP2024546851A (ja) * 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用

Also Published As

Publication number Publication date
IL300308A (en) 2023-04-01
WO2022029138A1 (en) 2022-02-10
MX2023001401A (es) 2023-05-03
CN116457344A (zh) 2023-07-18
US20240294489A1 (en) 2024-09-05
CA3186919A1 (en) 2022-02-10
AU2021319847A1 (en) 2023-03-02
EP4188373A1 (en) 2023-06-07
KR20230048373A (ko) 2023-04-11
BR112023001956A2 (pt) 2023-02-28

Similar Documents

Publication Publication Date Title
JP2023541522A (ja) 低分子量タンパク質分解物質及びその適用
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
CN111201223B (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
CN115989223B (zh) 使用CCR8抑制剂靶向Tregs的方法和组合物
JP7555938B2 (ja) アンドロゲン受容体を標的とするユビキチン化のための二官能性化合物および方法
CN102906090B (zh) 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
JP7759877B2 (ja) 治療用化合物
WO2021155321A2 (en) Compounds and uses thereof
KR20150128891A (ko) 인돌아민 2,3-디옥시게나제 (ido)의 억제제
CA2464790A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
KR20050086594A (ko) 세포 증식 장애를 위한 인돌린온과 화학요법제의 조합 투여
EA026723B1 (ru) Терапевтически активные соединения и способы их применения
AU2002360314A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
KR20120055571A (ko) 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸
CN112920176B (zh) 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用
CN111670183A (zh) 作为cdk8/19抑制剂的新型杂环化合物
US20040209937A1 (en) Treatment of excessive osteolysis with indolinone compounds
WO2012053787A2 (ko) Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
JP7138975B2 (ja) 新生物障害及び神経性障害の診断、治療及び予防のための組成物及び方法
CN118946569A (zh) 化疗药物和组织结合小分子的缀合物、其组合物和方法
EP4504209A1 (en) Method of treatment including kras g12c inhibitors and aurora a inhibitors
CN121591697A (zh) 靶向anxa3蛋白的1,4-苯二氮䓬类化合物及其药用用途
CN121045188A (zh) 1,2-二氢吡咯并[1,2-a]吡嗪-3(4H)-酮衍生物及其用途

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20230329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224